Skip to search formSkip to main contentSkip to account menu

BMS-911543

Known as: JAK2 Inhibitor BMS-911543 
An orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background Genetic variants in the transcription factor STAT4 are associated with increased susceptibility to systemic lupus… 
2016
2016
Introduction Treatment-resistant acute lymphoblastic leukemia (ALL) remains a significant clinical issue. Recently, genomic… 
2015
2014
2014
Activation of JAK2, frequently as a result of the JAK2V617F mutation, is a characteristic feature of the classical… 
2014
2014
Pancreatic cancer (PCa) is resistant to cytotoxic therapies, and the profound immune suppressive nature of this disease renders… 
2012
2012
Diffuse Large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin9s lymphoma, and is associated with variable clinical… 
2011
2011
Abstract 2743 The hallmark of chronic myeloid leukemia (CML) is the BCR-ABL fusion gene that originates in hematopoietic stem… 
2011
2011
Myeloproliferative diseases (MPDs) are a subset of myeloid malignancies that are characterized by the expansion of a multipotent… 
2010
2010
Abstract 4112 We report the characterization of BMS-911543, a potent and functionally selective small molecule inhibitor of the…